5440-65-3

Basic information

• Product Name: 3-methyl-2-propan-2-yl-butanamide
• Synonyms: 3-methyl-2-propan-2-yl-butanamide
• CAS NO: 5440-65-3
• Molecular Formula: C8H17NO
• Molecular Weight: 143.23
• Mol File: 5440-65-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 149 °C
• Boiling Point: 261.35°C (rough estimate)
• Flash Point: 119.7°C
• Appearance: /
• Density: 0.9636 (rough estimate)
• Vapor Pressure: 0.00547mmHg at 25°C
• Refractive Index: 1.4614 (estimate)
• PKA: 16.85±0.50(Predicted)
• Water Solubility: 4.3g/L(temperature not stated)
• CAS DataBase Reference: 3-methyl-2-propan-2-yl-butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-2-propan-2-yl-butanamide(5440-65-3)
• EPA Substance Registry System: 3-methyl-2-propan-2-yl-butanamide(5440-65-3)

Safety Data

• Hazardous Substances Data: 5440-65-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H17NO/c1-5(2)7(6(3)4)8(9)10/h5-7H,1-4H3,(H2,9,10)

Upstream product

• 62391-96-2 3-Methyl-2-isopropylbutyronitrile 
• 866-29-5 2-cyano-2-isopropyl-3-methyl-butyric acid 
• 7499-15-2 2,2-Diisopropylmalonsaeuremonoamid 
• 16933-64-5 3-Methyl-2-isopropyliden-buten-⁽³⁾-saeureamid 
• 7647-01-0 hydrogenchloride 
• 29571-64-0 2-isopropyl-3-methyl-butyryl chloride 
• 1000-87-9 2,4-dimethyl-2,3-pentadiene 

Downstream Products

• 32118-53-9 2-isopropyl-3-methylbutanoic acid 

Relevant articles and documents

Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues

Valproic acid (VPA, 1) is a major broad spectrum antiepileptic and central nervous system drug widely used to treat epilepsy, bipolar disorder, and migraine. VPA's clinical use is limited by two severe and lifethreatening side effects, teratogenicity and hepatotoxicity. A number of VPA analogues and their amide, N-methylamide and urea derivatives, were synthesized and evaluated in animal models of neuropathic pain and epilepsy. Among these, two amide and two urea derivatives of 1 showed the highest potency as antineuropathic pain compounds, with ED50 values of 49 and 51 mg/kg for the amides (19 and 20) and 49 and 74 mg/kg for the urea derivatives (29 and 33), respectively. 19, 20, and 29 were equipotent to gabapentin, a leading drug for the treatment of neuropathic pain. These data indicate strong potential for the above-mentioned novel compounds as candidates for future drug development for the treatment of neuropathic pain. 2009 American Chemical Society.

Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases

An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.